ML-179;3-cyclohexyl-6-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]-1H-pyrimidine-2,4-dione;2,4(1H,3H)-Pyrimidinedione, 3-cyclohexyl-6-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]-;3-cyclohexyl-6-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)pyrimidine-2,4(1H,3H)-dione;C57Bl6 mice,inhibit,SAA4,ER-negative breast cancer,probe compounds,ML 179,MCF-7,SAA1,Inhibitor,ML179,inverse;3-cyclohexyl-6-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}-1,2,3,4-tetrahydropyrimidine-2,4-dione;ML179, 10 mM in DMSO
ML-179 is a potent inverse agonist of liver receptor homolog-1 (LRH-1) (IC50 = 320 nM) with maximum efficacy of 40% repression. It is inactive at the related steroidogenic factor-1 transcriptional activator. Through LRH-1, ML-180 alters the expression of haptoglobin and serum amyloid proteins A1 and A4, induces the death of estrogen-receptor negative MDA-MB-231 breast cancer cells, and inhibits the steroidogenic acute regulatory promoter (IC50 = 2.12 μM).
